ERBB2 and non-small cell lung carcinoma: EMA-approved—breast (HER2+, HER2-low, metastatic, prior chemotherapy/HER2-targeted therapeutics), NSCLC (HER2-activating mutation, prior platinum chemotherapy), and gastric cancers (HER2+, advanced, prior trastuzumab therapy)